Who We Are
In 1968, Richard T. Silver, MD, a prominent oncologist, founded the Cancer Research & Treatment Fund (CR&T) with the belief that investing in blood cancer research would lead to important breakthroughs, as well as a better understanding of the biology and treatment of all forms of cancer. While the focus of the organization is the myeloproliferative neoplasms (MPNs), over the course of its 54-year history, CR&T has awarded more than $17 million in grants to research that has contributed to major advances in the fight against cancer.
Mission and Leadership
Cancer Research & Treatment Fund, Inc. (CR&T) funds research emphasizing the cause, prevention, treatment, and cure of myeloproliferative neoplasms (MPNs) and also funds other blood and solid tumor cancer research.
These grants fund cutting-edge blood and other cancer research, including clinical trials. The organization often acts as a first funder, providing seed capital for promising research initiatives. Innovative, agile, and experienced, CR&T is uniquely capable of moving quickly and effectively to advance the development of new treatments – and ultimately, to find cures.
Guided by a world-class Medical Advisory Board of physician-scientists, we carefully select each grant recipient. Our professionally diverse Board of Directors ensures that more than 80 cents of every dollar are spent directly on research and education. In addition, through our Young Professionals program, a new generation of leaders is bringing their talent and dedication to the organization.
Our Flagship Initiative: The Silver MPN Center
The Richard T. Silver, MD Myeloproliferative Neoplasm (MPN) Center at Weill Cornell Medicine in New York City was created in 2011 with a multi-million-dollar pledge from CR&T. Our goal is to help build the world’s leading center dedicated to cutting-edge research and outstanding care for people with MPNs.
We have already seen tremendous results from the work accomplished at the Center. Each year, papers are published in leading scientific journals and multiple abstracts are presented at the annual meeting of the American Society of Hematology (ASH), the world’s largest professional association serving clinicians and scientists who are dedicated to conquering blood cancers.
Every other year, CR&T hosts the International Patient Symposium on Myeloproliferative Neoplasms, an all-day educational event that enables patients and caregivers to learn about the latest developments in MPN research and treatments. Each presentation is videotaped and available to view in our video library.
The Cancer Survivor Hall of Fame Dinner, our signature event, is held every year in New York City and honors outstanding investigators and philanthropists, as well as courageous cancer survivors. The dinner raises significant funds in support of our mission. Guests can buy a single ticket or fill an entire table with friends, family, and colleagues.
A World Without Cancer
CR&T’s loyal friends and supporters make all of these achievements possible. We are deeply grateful for their commitment and look forward to the day when, together, we will celebrate our victory over cancer.